Evidence map›Paper›PMID 31703324›Full record

ArticlePharmaceutics2019

Fabrication of Ion-Crosslinking Aminochitosan Nanoparticles for Encapsulation and Slow Release of Curcumin.

Xiaoxiao Sun, Dongyan Yu, Zhuoyang Ying, Chuqiao Pan, Nan Wang, Fangfang Huang, Junhong Ling, Xiao-Kun Ouyang

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiaoxiao SunSchool of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China.
Dongyan YuSchool of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China.
Zhuoyang YingSchool of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China.
Chuqiao PanSchool of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China.
Nan WangSchool of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China.
Fangfang HuangSchool of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China.
Junhong LingSchool of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China.
Xiao-Kun OuyangSchool of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China.ORCID 0000-0002-8534-0279
Zhejiang Ocean University · CN

Funding

Bureau of Science and Technology of Zhoushan 2019C21023National Natural Science Foundation of China 21476212Science and Technology Department of Zhejiang Province 2018C02038
6 · The paper itself

Abstract

Curcumin (Cur) has anticancer activities but has poor stability, which can be improved using carrier materials. In this study, chitosan was aminated to increase the number of amino groups on its surface, modified with folic acid (FA), and then made into nanoparticles by ionic crosslinking. Owing to ion interaction, the negatively charged, non-toxic tripolyphosphate (TPP) interacted with the positively charged amino group on the aminated chitosan (AmCS) surface, producing FA-AmCS-TPP nanoparticles, which were then characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier transform infrared spectrophotometry (FT-IR), and thermogravimetric analysis (TGA). Their small particle size (175.2 ± 0.99 nm) and good surface positive potential (+42.4 mV) are beneficial for carrying antitumor drugs. We subsequently investigated whether coating of Cur by AmCS allows slow drug release by FA-AmCS-TPP nanoparticles in different pH environments, and estimated the Cur loading efficiency (EE-Cur). Our results showed that the cumulative release rate of Cur at 48 h was 56.2%, and that the EE-Cur reached 94.26 ± 0.91% with nanoparticles composed of 0.10 g AmCS, 10.0 mg FA, 10.0 mg TPP, and 15.0 mg Cur. Additionally, cytotoxicity experiments showed that the Cur/FA-AmCS-TPP nanoparticles had good targeting ability for tumor cells. Therefore, the non-toxic targeted composite nanoparticles had potential as a new antitumor agent that can overcome the limitations of Cur.

Indexed as

aminated chitosancurcuminfolic acidnanoparticlestargeted delivery

Identifiers

PMID31703324
PMCPMC6921002
OpenAlexW2983651968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.